Pre-exposure (PrEP)
Pre-exposure Prophylaxis (PrEP)
New Recommendations for Earlier HIV Screening and PrEP for Women
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Tuesday, 29 April 2014 00:00
- Written by ACOG
The American College of Obstetricians and Gynecologists last week issued 2 new recommendations on screening and prevention of HIV in women. The first matches the CDC's recommendation that HIV screening should start at age 13 and should be offered at least annually to at-risk women. The second advises that pre-exposure prophylaxis (PrEP) -- using antiretroviral medications such as Truvada to prevent HIV infection -- may be a useful tool for women at highest risk, including those with HIV positive male partners.
CROI 2014: Tenofovir Alone May Work as Well as Truvada for Pre-exposure Prophylaxis
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Tuesday, 08 April 2014 00:00
- Written by Liz Highleyman
Tenofovir used as a single agent for pre-exposure prophylaxis (PrEP) may be as effective as the Truvada (tenofovir/emtricitabine) coformulation for preventing HIV infection, which, if confirmed, could have implications for cost and access worldwide.
Most U.S. Providers Support PrEP, but Not Many Have Prescribed It
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Friday, 10 January 2014 00:00
- Written by Liz Highleyman
About three-quarters of infectious disease physicians in North America said they favored HIV pre-exposure prophylaxis (PrEP), but only 9% reported that they had prescribed Truvada (tenofovir/emtricitabine) for this purpose, according to a report in the December 6, 2013, advance edition of Clinical Infectious Diseases.
Truvada PrEP Did Not Cause Major Kidney Problems in HIV Prevention Trial
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Thursday, 20 February 2014 00:00
- Written by Liz Highleyman
Gay men who used Truvada (tenofovir/emtricitabine) for HIV pre-exposure prophylaxis (PrEP) were unlikely to develop impaired kidney function in the iPrEx study, according to a report in the February 4 advance edition of AIDS. Creatinine clearance decreased slightly on average among Truvada recipients, but returned to normal after stopping PrEP.
PrEP Does Not Promote Increased Sexual Risk Behavior among Gay Men
- Details
- Category: HIV Prevention
- Published on Monday, 23 December 2013 00:00
- Written by Liz Highleyman
Using Truvada (tenofovir/emtricitabine) for pre-exposure prophylaxis (PrEP) to prevent HIV infection was not associated with an increase in sex without condoms and it appears to promote active engagement in risk reduction, according to a report in the December 18, 2013, edition of PLoS ONE.
Web Design and Development by